{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T09:21:38Z","timestamp":1768296098336,"version":"3.49.0"},"reference-count":32,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T00:00:00Z","timestamp":1559001600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Aust Veterinary J"],"published-print":{"date-parts":[[2019,6]]},"abstract":"<jats:sec><jats:title>Case report<\/jats:title><jats:p>We describe the clinical signs and management of a case of anaphylaxis in a dog after intravenous administration of alphaxalone (Alfaxan\u00ae, Jurox, NSW, Aust), which has not been previously published. A female spayed cattle dog undergoing routine imaging for forelimb lameness was induced with Alfaxan after receiving sedation with acepromazine and methadone 70\u2009min prior. Immediately after intravenous administration of Alfaxan, the dog exhibited vomiting and diarrhoea associated with acute hypotension. Gallbladder wall oedema was visualised consistent with anaphylaxis. The dog responded to rapid volume expansion. Adrenaline was not required. The dog made a full recovery within 6\u2009h of the reaction and was re\u2010anaesthetised 3\u2009days later without incident, using propofol as the induction agent.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>To our knowledge, this is the first published case of anaphylaxis associated with intravenous Alfaxan in the dog. The APVMA reporting of reactions in small animals from 2003 to 2013 of Alfaxan is consistent with this case report's finding involving the respiratory, circulatory and gastrointestinal systems.<\/jats:p><\/jats:sec>","DOI":"10.1111\/avj.12824","type":"journal-article","created":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T17:00:17Z","timestamp":1559062817000},"page":"197-201","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Anaphylaxis associated with intravenous administration of alphaxalone in a dog"],"prefix":"10.1111","volume":"97","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3387-9982","authenticated-orcid":false,"given":"M","family":"Haworth","sequence":"first","affiliation":[{"name":"Veterinary Teaching Hospital University of Queensland  Gatton Queensland 4343 Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"McEwen","sequence":"additional","affiliation":[{"name":"Veterinary Teaching Hospital University of Queensland  Gatton Queensland 4343 Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Dixon","sequence":"additional","affiliation":[{"name":"Veterinary Teaching Hospital University of Queensland  Gatton Queensland 4343 Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SL","family":"Purcell","sequence":"additional","affiliation":[{"name":"Veterinary Medical Centre University of Queensland School of Veterinary Science  Gatton Queensland Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,5,28]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2006.01.018"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2010.06.022"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2003.12.591"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(84)90299-3"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/43.1.2-a"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tvjl.2014.12.011"},{"key":"e_1_2_5_8_1","unstructured":"Department of Health and Human Services. Food and Drug Administration. New animal drugs; approvals; changes of sponsor; change of sponsor's name; change of sponsor's address; Alfaxalone; Ivermectin and Clorsulon; Narasin; Triptorelin. 2012.https:\/\/www.gpo.gov\/fdsys\/pkg\/FR-2012\u201310\u201323\/htmL\/2012\u201325989.htm. Accessed June 2018."},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/51.9.819"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01964882"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/vr.107.21.481"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01716954"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/47.5.575"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.6089.735"},{"key":"e_1_2_5_15_1","first-page":"27","article-title":"Natural and synthetic neuroactive steroid modulators of GABAA and NMDA receptors","volume":"49","author":"Martinez\u2010Botella G","year":"2014","journal-title":"Annu Rep Med Chem"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/54.8.859"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.3.5977.205-a"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-94-015-7797-7_1"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.2460\/ajvr.69.11.1391"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-2995.2005.00264.x"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rvsc.2011.10.003"},{"key":"e_1_2_5_22_1","unstructured":"Australian Pesticides and Veterinary Medicines Authority. Adverse Experience Reporting Program annual reports.https:\/\/apvma.gov.au\/node\/10946. AccessedJune 2018."},{"key":"e_1_2_5_23_1","unstructured":"US Food and Drug Administration. Adverse Event Reporting for animal drugs and devices. USFDA 2018.https:\/\/www.fda.gov\/AnimalVeterinary\/SafetyHealth\/ProductSafetyInformation\/ucm055369.htm. Accessed June 2018."},{"key":"e_1_2_5_24_1","unstructured":"Veterinary Medicines Directorate. Veterinary medicines pharmacovigilance annual review reports. 18 April2017 updated 18 June 2018.https:\/\/www.gov.uk\/government\/collections\/veterinary\u2010medicines\u2010pharmacovigilance\u2010annual\u2010review\u2010reports. Accessed June 2018."},{"key":"e_1_2_5_25_1","unstructured":"Health Canada. Veterinary Drugs Directorate. Adverse drug reactions (Pharmacovigilance).2018.https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/veterinary-drugs\/adverse-drug-reactions-adrs.html. Accessed June 2018"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/vec.12066"},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-4431.2009.00474.x"},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1740-8261.1993.tb01576.x"},{"key":"e_1_2_5_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1978.tb17320.x"},{"key":"e_1_2_5_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-4431.2009.00480.x"},{"key":"e_1_2_5_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2007.01435.x"},{"key":"e_1_2_5_32_1","doi-asserted-by":"publisher","DOI":"10.1152\/jappl.1988.64.1.210"},{"key":"e_1_2_5_33_1","first-page":"005","article-title":"Anaphylactoid and anaphylactic study for three new injective excipients in beagle dogs","volume":"7","author":"Xingchao G","year":"2011","journal-title":"Chin Pharmaceut Affairs"}],"container-title":["Australian Veterinary Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/avj.12824","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/avj.12824","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/avj.12824","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T14:50:30Z","timestamp":1694357430000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/avj.12824"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,28]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["10.1111\/avj.12824"],"URL":"https:\/\/doi.org\/10.1111\/avj.12824","archive":["Portico"],"relation":{},"ISSN":["0005-0423","1751-0813"],"issn-type":[{"value":"0005-0423","type":"print"},{"value":"1751-0813","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,28]]},"assertion":[{"value":"2018-09-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-02-16","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}